A Single Center, Single Arm, Phase 2, Pilot Study to Investigate the Efficacy of the ACE Inhibitor Enalapril in Participants Aged 18-70 Years of Age with Painful Venous Malformations.

The goal of this clinical trial is to explore if enalapril can be used to treat painful venous malformations. The main question it aims to answer are:
- Can enalapril reduce pain and volume of the malformation and increase quality of life in patients with painful venous malformations?
Participants will:
Receive a dose of enalapril 5 mg once daily. If it doesn't have effect the dose of enalapril will be increased to 10 mg daily after 3 months.
The treatment duration will be 12 months, with an additional follow-up of 12 months.
The visit frequency will be after 1, 3, 6,9 and 12 months and then a follow up visit at 18 and 24 months.
Approximately 15 participants will be screened to achieve minimum 10 enrolled participants.

Start Date01 Feb 2025

Sponsor / Collaborator

Oslo universitetssykehus HF

CTRI/2024/11/076455

/ Not yet recruitingNot ApplicableIIT

Evaluation of efficacy of add on short course oral enalapril in children with infrequently relapsing nephrotic syndrome aged 1-18 years - A open labelled randomized controlled trial - NIL

Start Date14 Nov 2024

Sponsor / Collaborator-

CTIS2023-510076-31-00

/ Not yet recruitingPhase 2IIT

A single center, single arm, Phase 2, pilot study to investigate the efficacy of an angiotensin-converting enzyme inhibitor (ACE-inhibitor) in male and female participants aged 18-70 years of age with painful venous malformations.

Start Date14 Jun 2024

Sponsor / Collaborator-

100 Clinical Results associated with Enalapril Maleate

100 Translational Medicine associated with Enalapril Maleate

100 Patents (Medical) associated with Enalapril Maleate

12,180

Literatures (Medical) associated with Enalapril Maleate

01 May 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

Phloretin and Enalapril co-administration ameliorates hyperglycemia mediated exacerbation of myocardial injury in rats

Article

Author: Sharma, Prasanti ; Sharma, Neelima ; Bhattacharyya, Joydeep

Hyperglycemia exacerbates myocardial injury by amplifying oxidative stress, inflammation and apoptosis. This study explores the therapeutic potential of phloretin and enalapril co-administration in mitigating hyperglycemia-exacerbated myocardial damage. Using network pharmacology, 47 therapeutic targets and 10 hub genes, including albumin, insulin, prostaglandin endoperoxide synthase 2, matrix metallopeptidase 9, caspase3, tumor protein p53, insulin like growth factor 1, transforming growth factor beta 1, matrix metallopeptidase 2 and glycogen synthase kinase 3, were identified as critical to the drugs' synergistic action. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses highlighted key pathways, such as Interleukin-17 (IL-17), Advanced Glycation End Product-Receptor for Advanced Glycation End Products (AGE-RAGE), Mitogen activated protein kinase (MAPK), Phosphatidylinositol 3-kinase-protein kinase B (PI3K-Akt), Tumor necrosis factor (TNF) and Forkhead box O (FoxO), involved in angiogenesis, glucose metabolism, oxidative stress regulation and inflammation. Molecular docking confirmed strong affinities of phloretin and enalapril for key targets like insulin (INS), matrix metallopeptidase 9 (MMP9), prostaglandin endoperoxide synthase 2 (PTGS2) and insulin like growth factor 1 (IGF1). In-vivo studies using hyperglycemic rats with isoproterenol-induced myocardial ischemia validated the therapeutic efficacy of the combination. Co-treatment significantly enhanced antioxidant enzyme levels, reduced myocardial injury markers and improved histopathological features. These findings demonstrate the synergistic cardioprotective effects of phloretin and enalapril, offering a promising strategy for managing hyperglycemia and cardiac injury. The study provides a foundation for further preclinical and clinical evaluations to optimize the use of this combination in cardiovascular therapies.

01 Mar 2025·Analytical and Bioanalytical Chemistry

New robust and efficient liquid membranes for conductive vial electromembrane extraction of acids with low to moderate hydrophilicity in human plasma

Article

Author: Gaznawi, Somayeh ; Dowlatshah, Samira ; Hansen, Frederik André ; Hasvold, Grete ; Song, Chenchen ; Hay, Anne Oldeide

Abstract:

The current paper reports two new, robust, and efficient conditions for electromembrane extraction of acidic substances from human plasma. Two systems were developed based on eutectic solvents: A1 (“A” for acid) comprised dodecyl methyl sulfoxide and thymol in 1:2 ratio (w/w) as liquid membrane, while A2 used [6-methylcoumarin:thymol (1:2)]:2-nitrophenyl octyl ether in 2:1 ratio (w/w). The performance of A1 and A2 was characterized by extraction of 31 acidic model analytes (pharmaceutical drugs and nutrients) spiked into 100 µL human plasma diluted 1:1 (v/v) with phosphate buffer pH 7.4. The acceptor solution was 50 mM NH4HCO3 buffer pH 10.0, and extraction was performed at an agitation rate of 750 RPM. Voltage and extraction time were 30 V for 30 min and 10 V for 20 min for A1 and A2, respectively. Under optimal conditions, A1 extracted analytes with 1.8 ≤ log P ≤ 6.0 with an average recovery (R) of 85.1%, while A2 extracted in a range of 0.5 ≤ log P ≤ 6.0 with an average recovery of 79.9%. Meanwhile, extraction current was low at 9 and 26 µA, respectively, which is indicative of good system robustness. Using UHPLC-MS/MS analysis of the acceptor solution, repeatability of the A1 and A2 methods was determined to be 2.8–7.7% and 3.3–9.4% for R > 40%, matrix effects were 82–117% and 84–112%, respectively, and linear calibration curves were obtained. The performance and compatibility with human plasma represent a major improvement over previous state-of-the-art liquid membranes for acidic analytes, namely 1-octanol.Graphical Abstract

01 Mar 2025·OSTEOPOROSIS INTERNATIONAL

Osteoporotic fracture risks of thiazides and dihydropyridines in angiotensin modulator users

Article

Author: Chiang, Ping-Hao ; Wu, Wen-Shiann ; Lin, Yang-Chi ; Huang, Jing-Yang

PURPOSE:

To determine whether thiazides, combined with either angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB), offer bone-protective benefits compared with dihydropyridine (DHP) drugs combined with ACEi or ARB.

METHODS:

This retrospective cohort study was conducted on the US Collaborative Network from the TriNetX database on March 5th, 2024. It included hypertensive ACEi or ARB users under thiazide or DHP drug treatments spanning from January 1st, 2015, to December 31st, 2022, with exclusion criteria applied. The primary outcome is a composite typical osteoporotic fracture (TOPF). Kaplan Meier analyses were performed after 1:1 propensity-score matching (PSM) with a 5-year follow-up. Besides investigating fracture-related outcomes in thiazide-ACEi/ARB and DHP-ACEi/ARB users, this study explores whether the effects differ between ACEi and ARB users. Subgroup analyses were also performed, and the heterogeneity among the results was assessed using Cochran's Q-tests.

RESULTS:

Post-PSM results yield 54,240 patients per cohort in the primary analysis, aging 61.5 ± 12.2 versus 61.4 ± 13.7 (thiazide-ACEi/ARB versus DHP-ACEi/ARB) with predominantly white ethnicity. Thiazide-ACEi/ARB users exhibit lower TOPF risk than DHP-ACEi/ARB users (hazard ratio (HR) = 0.65, 95% confidence interval (CI) 0.61-0.70), and such benefits from thiazides are similar between ACEi and ARB users (ACEi: HR = 0.69; ARB: HR = 0.67, Cochran's Q-test p-value = 0.78). Additionally, the effects of thiazides reveal significant heterogeneity between patients with and without inflammatory polyarthropathy (ICD-10, M05-M14) and benzodiazepine usage (Cochran's Q-test p-value = 0.01, 0.04).

CONCLUSION:

Thiazides are associated with lower risks of typical osteoporotic fractures compared to DHP drugs in patients treated with ACEi or ARB, while such benefits may diminish in those with a diagnosis of inflammatory polyarthropathy and benzodiazepine usage.

News (Medical) associated with Enalapril Maleate

15 Feb 2024

·www.businesswire.com

GoodRx Now Offering 30 Common Heart Health Medications for Under $30

SANTA MONICA, Calif.--( BUSINESS WIRE )-- GoodRx , the leading destination for prescription savings in the U.S., today announced it is offering 30 of the most common heart health medications for under $30 at more than 70,000 pharmacies nationwide. 1 Cardiovascular disease is one of the most prominent conditions facing Americans, affecting nearly half of all U.S. adults. That’s why GoodRx is making it easier for all individuals, regardless of insurance status, to access savings on both generic and brand-name medications that mitigate the risk and impact of cardiovascular conditions such as coronary artery disease, high cholesterol, hypertension, and more. By helping people afford their prescriptions, GoodRx is improving health outcomes and reducing the overall strain on the healthcare system. GoodRx’s recent report - The GoodRx Effect - estimates that GoodRx has directly contributed to the prevention of at least 140,000 emergency room visits and 110,000 hospitalizations for major adverse cardiovascular events like heart attack and stroke. Save an average of 84% on common generic medications 2 The following is a sample list of common generic medications used to treat cardiovascular disease that are available for under $30 on GoodRx. MEDICATION LOWEST PRICE 3 AVG % SAVINGS 4 ACE Inhibitors Lisinopril (generic Prinivil and Zestril) $9.29 67% Enalapril (generic Epaned and Vasotec) $15.54 75% Beta Blockers Carvedilol (generic Coreg) $10.68 75% Metoprolol ER (generic Toprol XL) $11.15 74% Propranolol (generic Inderal) $10.96 71% Calcium Channel Blockers Amlodipine (generic Amvaz, Katerzia, and Norvasc) $9.15 80% Diltiazem ER (generic Cardizem CD) $13.43 74% Statins Atorvastatin (generic Lipitor) $10.10 83% Pravastatin (generic Pravachol) $14.53 74% Rosuvastatin (generic Crestor) $10.57 91% Access exclusive discounts and savings on brand-name drugs GoodRx offers incredible savings on brand-name medications that are often more costly and harder to obtain: MEDICATION SAVINGS* Entresto Pay as little as $10 for up to a 90-day supply Jardiance Pay as little as $10 per month Lodoco Pay as little as $30 for up to a 90-day supply Ozempic Pay as little as $25 per month Repatha Pay as little as $5 per month Soaanz Exclusive discount to save over 70% Toprol XL Exclusive discount to save up to 51% Xarelto Pay as little as $10 per fill *May require private or commercial insurance Learn more about cardiovascular disease from trusted doctors, pharmacists and health experts GoodRx Health is a go-to resource for understanding common heart conditions, risk factors, treatment options and associated savings. The GoodRx Heart Health Center provides credible, timely and actionable information to help people better manage their health. Each article is researched and written by a team of editorial experts, and clinical content is reviewed by a team of medical experts that includes physicians, pharmacists, and more. “Improving access to affordable medications is the most important thing we can do to improve Americans’ heart health. The second most important is ensuring access to helpful, accurate information,” said Karla Robinson, MD , Medical Editor at GoodRx. “Knowledge is power, so we create easy-to-understand content that people can actually use so they are better equipped to minimize the risk of disease, find affordable medications, stick to their treatment plans, and ultimately improve their overall health and wellbeing.” To find savings and trusted health information, download the GoodRx app or go to www.goodrx.com/hearthealth . About GoodRx GoodRx is the leading destination for prescription savings in the U.S. We offer consumers free access to transparent and lower prices for generic and brand medications, as well as comprehensive healthcare research and information. We also equip healthcare professionals with efficient ways to find and prescribe affordable medications. Since 2011, GoodRx has helped consumers save more than $65 billion and is one of the most downloaded medical apps over the past decade. GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com . We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding consumer savings; the benefits of our offerings to consumers, the U.S. healthcare system and GoodRx; and GoodRx’s plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits, changes in medication pricing and pricing structures, our reliance on a limited number of industry participants, the competitive nature of our industry, risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology and cyber-security and the important factors discussed in the section entitled “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2022, as updated by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and our other filings with the Securities and Exchange Commission. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. 1 Prices are subject to change at any time without notice. Prices may vary at different pharmacies, and for different forms, dosages, and quantities. 2 Calculated based on the difference between the average list price at a particular pharmacy and the average price paid by GoodRx consumers utilizing a GoodRx code at that same pharmacy in December 2023. 3 As of February 1, 2024. 4 Calculated based on the difference between the average list price at a particular pharmacy and the average price paid by GoodRx consumers utilizing a GoodRx code at that same pharmacy in December 2023.

AHA

08 Dec 2023

·synapse.patsnap.com

What are HMG-CoA reductase inhibitors and how do you quickly get the latest development progress?

HMG-CoA reductase is an enzyme that plays a crucial role in the human body's cholesterol synthesis pathway. It is responsible for catalyzing the conversion of HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) to mevalonate, a key precursor in the production of cholesterol. By regulating the activity of HMG-CoA reductase, the body can control the amount of cholesterol synthesized. This enzyme is the target of statin drugs, which inhibit its activity, leading to a reduction in cholesterol levels. Maintaining proper HMG-CoA reductase function is essential for maintaining cholesterol homeostasis and preventing the development of cardiovascular diseases. HMG-CoA reductase inhibitors, also known as statins, are a class of drugs used to lower cholesterol levels in the body. The first statin, lovastatin, was approved by the FDA in 1987. Since then, several other statins have been developed, including atorvastatin, simvastatin, and rosuvastatin. Statins work by inhibiting the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver. By reducing cholesterol levels, statins can help prevent heart attacks, strokes, and other cardiovascular diseases. In addition to their cholesterol-lowering effects, statins have been shown to have other beneficial effects, such as reducing inflammation and improving endothelial function. They have also been investigated for their potential to treat other conditions, such as Alzheimer’s disease, multiple sclerosis, and certain types of cancer. The future of HMG-CoA reductase inhibitors looks promising, with ongoing research into new statins and other cholesterol-lowering drugs. Researchers are also investigating the potential of statins to treat other diseases, such as osteoporosis and autoimmune disorders. However, there are also concerns about the long-term effects of statin use, such as an increased risk of diabetes and liver damage. As such, further research is needed to fully understand the benefits and risks of these drugs. The mechanism of action of HMG-CoA reductase inhibitorsHMG-CoA reductase inhibitors are a class of drugs commonly known as statins. From a biomedical perspective, these drugs are used to lower cholesterol levels in the blood. They work by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in the production of cholesterol in the liver. By blocking this enzyme, statins reduce the amount of cholesterol synthesized in the body, leading to a decrease in LDL (low-density lipoprotein) cholesterol, often referred to as "bad" cholesterol. Lowering LDL cholesterol levels can help prevent the development of cardiovascular diseases such as heart attacks and strokes. Additionally, statins may have other beneficial effects, such as reducing inflammation and improving the function of blood vessels. HMG-CoA reductase inhibitors are commonly prescribed to individuals with high cholesterol levels or those at risk of cardiovascular diseases. Catalog of HMG-CoA reductase InhibitorsThe currently marketed HMG-CoA reductase inhibitors include: Ezetimibe/Pitavastatin CalciumAtorvastatin/FimasartanFenofibrate/Pitavastatin CalciumAmlodipine Besylate/Fimasartan Potassium Trihydrate/Rosuvastatin CalciumAmlodipine Besylate/Olmesartan Medoxomil/Rosuvastatin CalciumAtorvastatin Calcium Hydrate/Metformin HydrochlorideAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilPitavastatin MagnesiumAmlodipine/Losartan Potassium/Rosuvastatin CalciumValsartan/Rosuvastatin CalciumFor more information, please click on the image below. What is the purpose of using HMG-CoA reductase inhibitors?HMG-CoA reductase inhibitors, are used to lower cholesterol levels in the body. They are used adjunctively with diet and exercise to treat and manage hypercholesterolemia (high cholesterol in blood) and for primary and secondary prevention of coronary heart disease. For more information, please click on the image below to log in and search. How can I get the most recent advancements in HMG-CoA reductase inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of HMG-CoA reductase inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

04 Sep 2023

·synapse.patsnap.com

ACE inhibitor -Overview of its R&D Progress | Competitive Landscape | Key Drug

ACE, or angiotensin-converting enzyme, plays a crucial role in the human body by regulating blood pressure and fluid balance. It converts angiotensin I, a hormone produced by the liver, into angiotensin II, a potent vasoconstrictor that narrows blood vessels. This process increases blood pressure and stimulates the release of aldosterone, a hormone that promotes sodium and water retention. ACE also breaks down bradykinin, a peptide that causes blood vessels to dilate and lowers blood pressure. Due to its involvement in these important physiological processes, ACE inhibitors are commonly used in the treatment of hypertension, heart failure, and other cardiovascular conditions. ACE Competitive LandscapeAccording to the data provided by Patsnap Synapse-Global Drug Intelligence Database: the following figure shows that as of 2 Sep 2023, there are a total of 163 ACE drugs worldwide, from 159 organizations, covering 68 indications, and conducting 810 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target. The analysis of the target ACE reveals a competitive landscape with companies like Les Laboratoires Servier SAS, CHIESI Farmaceutici SpA, and Viatris Inc. leading in R&D efforts. The focus of research is primarily on indications like hypertension, heart failure, and cardiovascular diseases. Small molecule drugs dominate the market, but there is also potential in other drug types like peptide drug conjugates and monoclonal antibodies. The European Union, China, the United States, and Japan are the key regions driving the development of ACE-related drugs. China, in particular, has shown significant progress. Overall, the target ACE presents opportunities for further research and development, with potential for innovative drugs and intense competition in the market. Key Drug: CaptoprilCaptopril is a small molecule drug that targets ACE and is used in the treatment of various cardiovascular, endocrinology, and urogenital diseases. It has been approved for multiple indications, including essential hypertension, hypertensive nephropathy, heart failure, and myocardial infarction. This wide range of indications highlights the versatility and effectiveness of Captopril in managing different conditions related to the cardiovascular system and metabolic disorders. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Captopril was first approved in Japan in January 1980, making it a well-established drug with a long history of use. The drug has achieved the highest phase of approval both globally and in China, indicating its widespread acceptance and recognition by regulatory authorities. This suggests that Captopril has undergone rigorous testing and evaluation to ensure its safety and efficacy Enalapril MaleateEnalapril Maleate is a small molecule drug that primarily targets ACE. It is used in the treatment of various therapeutic areas including immune system diseases, infectious diseases, nervous system diseases, cardiovascular diseases, and urogenital diseases. The drug has been approved for the treatment of ventricular dysfunction, left, angina pectoris, myocardial infarction, encephalomyelitis, eastern equine, immune system diseases, heart failure, essential hypertension, hypertension, renal, hypertension, renovascular, and hypertension. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Enalapril Maleate has a long history of use since its first approval in 1985. Its broad therapeutic areas and indications make it a versatile drug in the field of biomedicine. The drug's approval in both the global and Chinese markets further solidifies its position as a widely recognized and accepted treatment option. As a small molecule drug targeting ACE, Enalapril Maleate plays a crucial role in managing various diseases and conditions, particularly those related to the immune system, cardiovascular system, and nervous system. LisinoprilLisinopril is a small molecule drug that falls under the therapeutic area of cardiovascular diseases. It primarily targets ACE and is used to treat various conditions related to the heart and blood vessels. The drug has been approved for use in multiple indications, including acute myocardial infarction, kidney diseases, chronic heart failure, hypertension, and heart failure. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Lisinopril was first approved in the United States in December 1987 and has been developed by Merck Sharp & Dohme Corp. and AstraZeneca PLC. Lisinopril has reached the highest phase of development, indicating its safety and efficacy, and has received regulatory approval both globally and in China.

100 Deals associated with Enalapril Maleate

External Link

KEGG	Wiki	ATC	Drug Bank
D00621	Enalapril Maleate	C09AA02	DB00584

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ventricular Dysfunction, Left	United States	Azurity Pharmaceuticals, Inc.	20 Sep 2016
Angina Pectoris	China	Merck Sharp & Dohme Corp.	15 Dec 2000
Myocardial Infarction	China	Merck Sharp & Dohme Corp.	15 Dec 2000
Encephalomyelitis, Eastern Equine	United States	Wockhardt Ltd.	22 Aug 2000
Immune System Diseases	United States	Wockhardt Ltd.	22 Aug 2000
Heart Failure	Japan	Organon & Co.	29 Mar 1991
Essential Hypertension	Japan	Organon & Co.	30 Apr 1986
Hypertension, Renal	Japan	Organon & Co.	30 Apr 1986
Hypertension, Renovascular	Japan	Organon & Co.	30 Apr 1986
Hypertension	United States	Bausch Health US LLC	24 Dec 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic heart failure	Phase 3	Austria	Ethicare, Inc.	01 Mar 2016
Chronic heart failure	Phase 3	Hungary	Ethicare, Inc.	01 Mar 2016
Chronic heart failure	Phase 3	Netherlands	Ethicare, Inc.	01 Mar 2016
Chronic heart failure	Phase 3	Serbia	Ethicare, Inc.	01 Mar 2016
Chronic heart failure	Phase 3	United Kingdom	Ethicare, Inc.	01 Mar 2016
Cardiomyopathy, Dilated	Phase 3	Austria	Ethicare, Inc.	01 Jan 2016
Cardiomyopathy, Dilated	Phase 3	Hungary	Ethicare, Inc.	01 Jan 2016
Cardiomyopathy, Dilated	Phase 3	Netherlands	Ethicare, Inc.	01 Jan 2016
Cardiomyopathy, Dilated	Phase 3	Serbia	Ethicare, Inc.	01 Jan 2016
Cardiomyopathy, Dilated	Phase 3	United Kingdom	Ethicare, Inc.	01 Jan 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03179163 (H2SPharm, CTgov)	Phase 1/2	Essential Hypertension	10	Captopril	xpgztmkwie(iifsvtjjhi) = ghqwssfjfn nrrlxsbocb (qtzfivglug, 47) View more	-	28 Feb 2024
ESC2023	Not Applicable	First line	-	Perindopril-based regimens	dvzgoakfdb(fezzkqwwjz) = reqvpcfpfv yeyvvtefla (ctnlishqkb, 87–8973)	-	27 Aug 2023
				Losartan-based regimens	dvzgoakfdb(fezzkqwwjz) = gcmxsxqsdx yeyvvtefla (ctnlishqkb, 104–9365)
NCT04236258 (CTgov)	Phase 4	Pre-Eclampsia	94	NIFEdipine ER (Nifedipine)	qwsfeswwzs = bvylqjhxaj nglrakztgt (deatijfiwa, enytfrqiyc - prccbgxebc) View more	-	30 Nov 2022
				Enalapril (Enalapril)	qwsfeswwzs = icdinaskfn nglrakztgt (deatijfiwa, btgszttqam - mmgtubvbcq) View more
ESC2021	Not Applicable	Hematologic Neoplasms	60	Sacubitril/Valsartan	ajbkthaphm(dcimcdgrti) = hoatnetzhy ipsqvozojx (geegkpbmjj )	Positive	09 Dec 2021
				Enalapril	ajbkthaphm(dcimcdgrti) = irndvbmqkk ipsqvozojx (geegkpbmjj ) View more
NCT01754909 (CTgov)	Phase 2	Radiation Pneumonitis \| Lung Cancer \| Fibrosis	50	enalapril (Enalapril)	lyalinjtwg = svsizawvpg yjyogtyybc (etgaemcbsc, nsmqiadtlc - gnwlatajwe) View more	-	01 Oct 2019
				placebo (Placebo)	lyalinjtwg = pdnqolibpf yjyogtyybc (etgaemcbsc, rvfkvgjppd - pjtmgwhgww) View more
NCT00895414 (CTgov)	Not Applicable	Breast Cancer	19	doxorubicin hydrochloride+enalapril maleate (Doxorubicin Alone First, Then Doxorubicin With Enalapril)	njmfstpphp(ooxhjrffdo) = yodmpdgiut vroxkhbenp (gcqjemakgs, mhucufspyz - mbpykhxmkf) View more	-	08 May 2019
				doxorubicin hydrochloride+enalapril maleate (Doxorubicin With Enalapril First, Then Doxorubicin Alone)	njmfstpphp(ooxhjrffdo) = qpcmnictyu vroxkhbenp (gcqjemakgs, ecsksbteon - zoanqwzygj) View more
NCT01035255 (PARADIGM-HF, Pubmed \| Eur J Heart Fail)	Phase 3	Heart failure with reduced ejection fraction \| Chronic heart failure	8,399	Sacubitril/valsartan	ckyhtzpdsg(rwbgwsvzqy) = dedllidgyy nraivtflty (xgxjhpzale )	-	01 Mar 2019
				Enalapril	ckyhtzpdsg(rwbgwsvzqy) = kjlocbcuec nraivtflty (xgxjhpzale )
NCT02554890 (PIONEER-HF, Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 4	Acute decompensated heart failure	881	sacubitril-valsartan	atvylctlks(wicnvdlgrq) = lpdttgjqtm dakkfjimvh (njotoaxdum )	Positive	07 Feb 2019
				enalapril	atvylctlks(wicnvdlgrq) = urcbnivlcj dakkfjimvh (njotoaxdum )
ESC2018	Not Applicable	Chronic heart failure First line	-	Enalapril	folrrsorcr(bphethqfdg) = vakxkiivev mynjbgyobt (vodfyzdjbb )	-	26 May 2018
				Lisinopril	folrrsorcr(bphethqfdg) = wmrzkzilkc mynjbgyobt (vodfyzdjbb )
SP268 (ERA2018)	Not Applicable	Chronic Kidney Diseases	813	RAS blockers monotherapy	jzoedhffxw(iokjumkuwq) = kvbqpfghnm hzqvezhgux (oibxrtytsp )	Negative	18 May 2018
				Dual RAS blockade	jzoedhffxw(iokjumkuwq) = xqocxhxxpg hzqvezhgux (oibxrtytsp )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Enalapril Maleate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation